Analyst consensus rating
Pacira BioSciences Analyst Rating: Buy
PCRX is rated Buy by 7 analysts with a $30.00 target. As of 2026-09-02.
Direct answer
Pacira BioSciences's consensus rating is Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.00.
Forecast evidence checked September 2, 2026.
Get free Pacira BioSciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $26.82
- Average price target
- $30.00
- High price target
- $38.00
- Low price target
- $23.00
- Low target gap
- -14.2%
- Target upside
- +11.9%
- High target gap
- +41.7%
- Target range width
- 55.9%
- Consensus rating
- Buy
- Analysts
- 7
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Pacira BioSciences?
Pacira BioSciences has a verified Buy consensus. The same dataset has an average price target of $30.00.
How far are Pacira BioSciences's low and high targets from the recorded price?
The low target implies -14.2%, while the high target implies +41.7%.
How many analysts are included in Pacira BioSciences's consensus?
The verified consensus includes 7 analysts.
How is Pacira BioSciences's target upside or downside calculated?
The average target of $30.00 is divided by the recorded price of $26.82, then one is subtracted to produce +11.9%. This does not guarantee a future return.
When was Pacira BioSciences's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.